Jazz Pharmaceuticals: Regulation Fd Disclosure, Financial Statements And Exhibits

Item 7.01 Regulation FD Disclosure. On August 10, 2026, Jazz Pharmaceuticals Public Limited Company (“Jazz”) and Actio Biosciences, Inc. (the “Company”) issued a joint press release. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference. The information contained in this report, including Exhibit 99.1 attached hereto, is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by Jazz regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated August 10, 2026, jointly issued by Jazz Pharmaceuticals Public Limited Company and Actio Biosciences, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * * * * * SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY By: /s/ Philip L. Johnson Name: Philip L. Johnson Title: Executive Vice President and Chief Financial Officer Date: August 10, 2026

Jazz Pharmaceuticals: Regulation Fd Disclosure, Financial Statements And Exhibits

Şirketle ilgili diğer haberler